Free versus total ligand-binding assays: Points to consider in biotherapeutic drug development

Bioanalysis

Volumn 3, Issue 11, 2011, Pages 1163-1165

  Yang, Jihong ^a   Quarmby, Valerie ^a  

^a GENENTECH INC   (United States)

Author keywords

biotherapeutic drug development; ELISA; ligand binding assay; monoclonal antibody; pharmacodynamic; pharmacokinetics

Indexed keywords

MONOCLONAL ANTIBODY; OKT 3;

DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; LIGAND BINDING; PHARMACODYNAMICS; PUBLICATION; REVIEW;

DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES;

EID: 79958731050     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.73     Document Type: Review

References (6)

1. Smith SL. Ten years of orthoclone OKT3 (muromonab-CD3): a review. J. Transpl. Coord. 6(3), 109-119, quiz 120-121 (1996).
2. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548-558 (2008).
3. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
4. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6), 1125-1140 (2010).
5. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76, (2009).
6. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res. 70(23), 9886-9894 (2010).